| Product NDC: | 53489-141 |
| Proprietary Name: | Quinidine Gluconate |
| Non Proprietary Name: | Quinidine Gluconate |
| Active Ingredient(s): | 324 mg/1 & nbsp; Quinidine Gluconate |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET, EXTENDED RELEASE |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 53489-141 |
| Labeler Name: | Mutual Pharmaceutical |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA089338 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 19870210 |
| Package NDC: | 53489-141-03 |
| Package Description: | 250 TABLET, EXTENDED RELEASE in 1 BOTTLE (53489-141-03) |
| NDC Code | 53489-141-03 |
| Proprietary Name | Quinidine Gluconate |
| Package Description | 250 TABLET, EXTENDED RELEASE in 1 BOTTLE (53489-141-03) |
| Product NDC | 53489-141 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Quinidine Gluconate |
| Dosage Form Name | TABLET, EXTENDED RELEASE |
| Route Name | ORAL |
| Start Marketing Date | 19870210 |
| Marketing Category Name | ANDA |
| Labeler Name | Mutual Pharmaceutical |
| Substance Name | QUINIDINE GLUCONATE |
| Strength Number | 324 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Antiarrhythmic [EPC],Cytochrome P450 2D6 Inhibitor [EPC],Cytochrome P450 2D6 Inhibitors [MoA] |